Mithridion CEO Trevor Twose collaborated with an Ohio firm to survive.
In the business world, the path to success is not always straight ahead. And in biotechnology, the route can be even more circuitous, often hitting a dead end.
That could have happened to Mithridion, a Madison company developing drugs to fight Alzheimer’s disease and schizophrenia.
The company had just been formed when it won the Wisconsin Governor’s Business Plan Contest in 2005. But the accolades didn’t help much when, two years later, researchers realized Mithridion’s drug candidate didn’t work.
Read full State Journal article here.